| Original language | English (US) |
|---|---|
| Pages (from-to) | 817-819 |
| Number of pages | 3 |
| Journal | JAMA Dermatology |
| Volume | 156 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2020 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. / Khurana, Sharad; Sluzevich, Jason C.; He, Rong et al.
In: JAMA Dermatology, Vol. 156, No. 7, 07.2020, p. 817-819.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Association between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing
AU - Khurana, Sharad
AU - Sluzevich, Jason C.
AU - He, Rong
AU - Reimer, Danielle K.
AU - Kharfan-Dabaja, Mohamed A.
AU - Foran, James M.
AU - Jiang, Liuyan
N1 - Funding Information: Funding/Support: This research was supported in part by the Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences. Role of the Funder/Sponsor: The Intramural Research Program of the National Cancer Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Environmental Health Sciences played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patients for granting permission to publish this information. We also thank Marcus Chen, MD, National Heart, Lung, and Blood Institute, National Institutes for Health, for assistance with computed tomographic imaging and Dominique C. Pichard, MD, Dermatology Branch, National Institutes for Health, for her help in reviewing the final manuscript. Funding Information: Conflict of Interest Disclosures: Dr Kharfan-Dabaja has served as a consultant for Daiichi Sankyo and Pharmacyclics. Dr Foran has received personal fees from Agios, Pfizer, Stemline, Novartis, and AbbVie and grants from Boehringer Ingelheim, Xencor, Kura, Takeda Millennium, and Actinium. No other conflict of interest disclosures were reported.
PY - 2020/7
Y1 - 2020/7
UR - http://www.scopus.com/inward/record.url?scp=85084795650&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084795650&partnerID=8YFLogxK
U2 - 10.1001/jamadermatol.2020.0544
DO - 10.1001/jamadermatol.2020.0544
M3 - Letter
C2 - 32374348
AN - SCOPUS:85084795650
VL - 156
SP - 817
EP - 819
JO - Archives of Dermatology
JF - Archives of Dermatology
SN - 2168-6068
IS - 7
ER -